Advaxis trades as part of the healthcare sector and is in the biotechnology industry. The company CEO is Kenneth A. Berlin. Advaxis Inc focuses on discovery, development, and commercialization of proprietary Lm Listeria monocytogenes-LLO Listeriolysin O cancer immunotherapies.



Previous Intraday Performance:

The ADXS shares had a previous change of -0.34% which opened at 3.00 and closed at 2.94. It moved to an intraday high of 3.02 and a low of 2.92.

SeekingAlpha:  ADXS, CLRB among premarket gainers

Historical Performance:

Over the last five trading days, ADXS shares returned -2.65% and in the past 30 trading days it returned -17.18%. Over three months, it changed -45.78%. In one year it has changed -89.05% and within that year its 52 week high was 29.40 and its 52 week low was 2.72. ADXS stock is 8.29% above its 52 week low.

Our calculations result in a 200 day moving average of 8.33 and a 50 day moving average of 4.29. Right now, ADXS stock is trading -64.72% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.

SeekingAlpha:  FDA lifts partial hold on late-stage study of Advaxis’ AXAL

Liquidity:

The company has a market cap of $23.5m with 8.0m shares outstanding and a float of 3.6m shares. Trading volume was 41,833 shares and has experienced an average volume of 273,373 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.

Earnings:

The last annual reported EPS for Advaxis was -19.8 which ended on 31st of October 2018. Based on 1 analyst estimate, the estimated EPS for the next quarter is -4.20.

Below was the last reported quarterly diluted earnings per share:

Jan19 2.70
Oct18 -4.35
Jul18 -4.05
Apr18 -4.05
Jan18 -7.35

The next earnings report will be: 06-11-2019

EPS growth is an important number as it indicates the future prospects of Advaxis; the EPS growth rate, as it is typically called, is usually expressed as a percentage, which at this time is hard to estimate, but revenue growth has been 41.50% over the last twelve months.



Indicators Also to Watch:

Based on the latest filings, there is 19.90% of institutional ownership.

The beta was calculated to be 3.68.

Business Wire:  FDA Lifts Partial Clinical Hold on Phase 3 AIM2CERV Study of Axalimogene Filolisbac

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is -90.11%, return on assets is -54.57%, price-to-sales is 1.08 and price-to-book is 0.63.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 4  : Financial Safety Result
 0  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 1  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).

LEAVE A REPLY

Please enter your comment!
Please enter your name here